Health Technology · Pharmaceuticals: Major · NSE: HIKAL · data 2026-10-09

Hikal Limited

Health check: Weak (2.2/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹213.66

Market cap

₹2,611 cr

P/E

—

P/B

—

ROE

-4.0%

ROCE

3.1%

Debt / equity

0.57

Dividend yield

0.28%

1-year return

-14.6%

52-week high

₹261

52-week low

₹146.25

Operating margin

3.8%

Growth

Revenue (last 12 months)	₹1,735 cr
Net profit (last 12 months)	₹-34 cr
Sales growth, 3 years (yearly)	-5.4%
Profit growth, 3 years (yearly)	—

Chart patterns

Descending triangle — forming (key level ₹203.83)

Similar companies

Shukra Pharmaceuticals Ltd. (SHUKRAPHAR) · Alembic Limited (ALEMBICLTD) · Fredun Pharmaceuticals Ltd. (FREDUN) · Dishman Carbogen Amcis Ltd. (DCAL) · Venus Remedies Limited (VENUSREM)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open HIKAL in NSE Scanner →